TMCITREACE MEDICAL CONCEPTS, INC.

Nasdaq treace.com


$ 5.28 $ 0.22 (4.35 %)    

Tuesday, 17-Sep-2024 15:38:41 EDT
QQQ $ 472.78 $ -3.19 (-0.67 %)
DIA $ 416.60 $ -1.39 (-0.33 %)
SPY $ 562.10 $ -3.03 (-0.54 %)
TLT $ 100.93 $ -0.46 (-0.45 %)
GLD $ 237.37 $ -0.61 (-0.26 %)
$ 5.01
$ 5.06
$ 5.27 x 140
$ 5.28 x 121
$ 5.06 - $ 5.52
$ 3.92 - $ 15.98
519,714
na
311.57M
$ 1.23
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2024 06-30-2024 10-Q
2 05-07-2024 03-31-2024 10-Q
3 02-27-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-09-2023 06-30-2023 10-Q
6 05-09-2023 03-31-2023 10-Q
7 03-08-2023 12-31-2022 10-K
8 11-09-2022 09-30-2022 10-Q
9 08-10-2022 06-30-2022 10-Q
10 05-06-2022 03-31-2022 10-Q
11 03-04-2022 12-31-2021 10-K
12 11-04-2021 09-30-2021 10-Q
13 08-05-2021 06-30-2021 10-Q
14 05-25-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 treace-highlights-new-product-innovations-and-updated-clinical-study-data-at-the-aofas-annual-meeting-2024

Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a...

 ubs-maintains-neutral-on-treace-medical-concepts-raises-price-target-to-7

UBS analyst Danielle Antalffy maintains Treace Medical Concepts (NASDAQ:TMCI) with a Neutral and raises the price target fro...

 truist-securities-maintains-hold-on-treace-medical-concepts-lowers-price-target-to-75

Truist Securities analyst Richard Newitter maintains Treace Medical Concepts (NASDAQ:TMCI) with a Hold and lowers the price ...

 treace-medical-concepts-reaffirms-fy24-revenue-guidance-of-201m---211m-est-205405m

The Company continues to expect Adjusted EBITDA to improve approximately 50% compared to full-year 2023.*

 treace-medical-concepts-q2-2024-gaap-eps-034-misses-029-estimate-sales-44455m-beat-43000m-estimate

Treace Medical Concepts (NASDAQ:TMCI) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimat...

 truist-securities-maintains-hold-on-treace-medical-concepts-raises-price-target-to-9

Truist Securities analyst Richard Newitter maintains Treace Medical Concepts (NASDAQ:TMCI) with a Hold and raises the price ...

 morgan-stanley-maintains-equal-weight-on-treace-medical-concepts-raises-price-target-to-8

Morgan Stanley analyst Drew Ranieri maintains Treace Medical Concepts (NASDAQ:TMCI) with a Equal-Weight and raises the price...

 ubs-downgrades-treace-medical-concepts-to-neutral-lowers-price-target-to-65

UBS analyst Danielle Antalffy downgrades Treace Medical Concepts (NASDAQ:TMCI) from Buy to Neutral and lowers the price targ...

 orthopedic-devices-maker-treace-medical-concepts-gloomy-forecast-cast-concerns-over-long-term-viability

Treace Medical Concepts reports Q1 EPS loss of $(0.30), sales hit $51.11 million, up 21%. Surge in procedure kits sold due to e...

 morgan-stanley-downgrades-treace-medical-concepts-to-equal-weight-lowers-price-target-to-55

Morgan Stanley analyst Drew Ranieri downgrades Treace Medical Concepts (NASDAQ:TMCI) from Overweight to Equal-Weight and low...

 ubs-maintains-buy-on-treace-medical-concepts-lowers-price-target-to-16

UBS analyst Danielle Antalffy maintains Treace Medical Concepts (NASDAQ:TMCI) with a Buy and lowers the price target from $1...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION